2009's Top Biopharma Dealmakers
Executive Summary
A flurry of dealmaking in December, especially by big pharmacos, helped to bring 2009 to a strong close in terms of alliances. But the year will probably most be remembered for the Big Pharma mega mergers that combined four major companies and topped the acquisitions list by their dollar values. We focus here on the dealmakers, showing which companies dominated the dealmaking landscape in terms of deal volume and value, as well as therapeutic categories that grabbed the most attention.